Results 21 to 30 of about 193,360 (208)

Circulating thrombopoietin levels in normal healthy blood donors and in aplastic anemia patients in relation to disease severity

open access: yesAsian Journal of Transfusion Science, 2015
Background: Thrombopoietin (TPO) is the key hematopoietic growth factor regulating the production of platelets from bone marrow megakaryocytes and maintaining platelet hemostasis.
Abhay Singh   +4 more
doaj   +1 more source

Proposed protocol for treatment of severe periodontitis without platelet transfusion in patients with aplastic anemia: a case report

open access: yesJournal of Medical Case Reports, 2021
Background Aplastic anemia is an intractable disease characterized by pancytopenia, susceptibility to infection, and difficulty in achieving hemostasis.
Satoru Morikawa   +4 more
doaj   +1 more source

A plasma microRNA signature as a biomarker for acquired aplastic anemia

open access: yesHaematologica, 2017
Aplastic anemia is an acquired bone marrow failure characterized by marrow hypoplasia, a paucity of hematopoietic stem and progenitor cells, and pancytopenia of the peripheral blood, due to immune attack on the bone marrow.
Kohei Hosokawa   +9 more
doaj   +1 more source

Cyclosporine A and Romiplostim as a Bridging Therapy to Curative Surgery in Aplastic Anemia Complicated by Gastric Cancer: A Case Report. [PDF]

open access: yesEJHaem
ABSTRACT We present a case of aplastic anemia (AA) complicated with gastric cancer that was successfully treated with cyclosporine A (CsA) and romiplostim (ROMI) as a bridging therapy before curative surgery. This patient had untreated gastric cancer at the time of AA diagnosis, and surgery was difficult because of thrombocytopenia.
Nakagawa N, Yamazaki M, Hosokawa K.
europepmc   +2 more sources

ELTROMBOPAG THERAPHY IN CASES OF APLASTIC ANEMIA: A CASE REPORT

open access: yes, 2023
: Eltrombopag Theraphy In Cases Of Aplastic Anemia: A Case Report. Management of cases of aplastic anemia is challenge. The definitive treatment is bone marrow transplantation, but it is expensive, the complication rate is high and the success rate is ...
Suastika, Ngakan Ketut Wira   +1 more
core   +1 more source

Severe retinal hemorrhages at various levels with a serous retinal detachment in a pediatric patient with aplastic anemia–A case report

open access: yesFrontiers in Medicine, 2023
BackgroundAplastic anemia can cause ophthalmic abnormalities in patients. Vision loss in a child with aplastic anemia due to massive retinal hemorrhages at various levels is rare.Case presentationA pediatric patient with aplastic anemia presented with ...
Xiaoshuang Jiang   +4 more
doaj   +1 more source

Thymoma followed by aplastic anemia: two different responses to immunosuppressive therapy

open access: yesRevista Brasileira de Hematologia e Hemoterapia, 2011
Aplastic anemia is an uncommon complication of thymoma and is extremely infrequent after the surgical removal of a thymic tumor. Aplastic anemia is a result of marrow failure and is characterized by peripheral pancytopenia and severely depressed marrow ...
Murilo Antunes de Castro   +3 more
doaj   +1 more source

Syngeneic peripheral blood stem cell transplantation with immunosuppression for hepatitis-associated severe aplastic anemia

open access: yesTurkish Journal of Hematology, 2010
Hepatitis-associated aplastic anemia occurs in up to 10% of all aplastic anemia cases. Syngeneic bone marrow transplantation is rare in patients with severe aplastic anemia and usually requires pre-transplant conditioning to provide engraftment.
Aleksandar Savic   +6 more
doaj   +3 more sources

Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic stem cell transplantation

open access: yesHaematologica, 2014
A proportion of patients with aplastic anemia who are treated with immunosuppressive therapy develop clonal hematologic disorders, including post-aplastic anemia myelodysplastic syndrome.
Sung-Yong Kim   +10 more
doaj   +1 more source

Effectiveness of Iptacopan Versus C5 Inhibitors in Complement Inhibitor‐Naive Patients With Paroxysmal Nocturnal Haemoglobinuria

open access: yeseJHaem
Background Paroxysmal nocturnal haemoglobinuria (PNH) is characterised by haemolytic anaemia, bone marrow failure and thrombosis. The single‐arm phase 3 APPOINT‐PNH trial (NCT04820530) investigating iptacopan monotherapy in complement inhibitor‐naive ...
Matthew Holt   +8 more
doaj   +1 more source

Home - About - Disclaimer - Privacy